Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

HGH Fragment 176-191 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established HGH Fragment 176-191 cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • HGH Fragment 176-191 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established HGH Fragment 176-191 cycle length?
No. We found no human studies that report a treatment duration for HGH Fragment 176-191.
What is the longest human study of HGH Fragment 176-191?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
HGH Fragment 176-191 dosing reference Full research page

References

  1. Drugs@FDA application data queried through openFDA for hGH fragment 176-191 and AOD-9604 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  2. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  3. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells Drug Des Devel Ther. 2022
  4. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone Am J Physiol. 1978
  5. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone Biochem Mol Biol Int. 1993
  6. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Horm Res. 2000
  7. PubChem compound record for human growth hormone fragment 176-191 (CID 172966176) PubChem. 2026
  8. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (describes AOD9604 as hGH 176-191 with an added N-terminal tyrosine and summarises the limited human evidence) Front Endocrinol (Lausanne). 2026